Tell us what's important to you. We'll build you a better ClevelandClinic.org.

close

Take the ClevelandClinic.org Improvement Survey Now!

Online Health Chat.Access Our A-Z Phone Directorybenefiting the communityOnline Health Chat.

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Print this ContentEmail this Content
Study:

Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin

Rationale:

Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Purpose:

This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors.

Study Status: Recruiting

Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Condition Intervention Phase
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer
Testicular Germ Cell Tumor		 Drug: carboplatin
Drug: filgrastim
Drug: ifosfamide
Drug: paclitaxel		 Phase 2

Verified by Children`s Oncology Group September, 2008

Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00467051

Study Type: Interventional

Study Design: Treatment, Open Label

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Carlos Rodriguez-Galindo, MD., Study Chair
A. Lindsay Frazier, MD.,

This information is abbridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.